Health Catalyst divests Vitalware to Med-Metrix for $147m
Health Catalyst (Nasdaq: HCAT) has signed a definitive agreement to sell Vitalware, its mid-revenue cycle business, to revenue cycle management specialist Med-Metrix for $147 million in cash. The Salt Lake City-based healthcare intelligence company said the divestiture sharpens its focus on AI-driven clinical and operational improvement for health systems.
The deal marks a significant structural pivot for Health Catalyst. Net proceeds, combined with cash on hand, are intended to fully repay and terminate the company's existing senior secured term loan, which carried approximately $160 million of outstanding principal as at 31 March 2026, plus interest, prepayment premiums, and associated costs. Retiring that facility will materially reduce the company's debt burden and, management argues, free capital for technology investment.
The deal
Vitalware generated roughly $37 million in revenue in its 2025 fiscal year and holds a best-in-KLAS designation for its category. The product suite covers chargemaster management, coding compliance, charge capture, and price transparency — tools that sit squarely in the financial operations layer of a health system, rather than the clinical and outcomes improvement work Health Catalyst is positioning as its core business.
Chief executive Ben Albert described the transaction as "a big step forward," adding that the company intends to put "the capital structure in place to back our long-term strategy." Med-Metrix, which provides technology-enabled revenue cycle management to provider organisations across the United States, was characterised as well positioned to invest more deeply in the Vitalware product line.
Raymond James acted as exclusive financial adviser to Health Catalyst; Latham & Watkins served as outside legal counsel. The transaction is expected to close in 2026, subject to the expiration or termination of applicable regulatory waiting periods. Health Catalyst filed an 8-K with the Securities and Exchange Commission on 4 June 2026.
Strategic context
Health Catalyst's stated AI roadmap is built on 18 years of proprietary healthcare improvement data and what the company describes as $2.8 billion in documented measurable outcomes. The logic of the divestiture is that owning a mid-revenue cycle software business dilutes that narrative and consumes management bandwidth that could otherwise be directed towards the analytics and AI platform.
The broader market for healthcare data and AI platforms is competitive and evolving rapidly. A number of well-capitalised vendors — spanning pure-play health data companies, large enterprise software groups, and specialist AI start-ups — are all competing for the same health system budgets. Analysts will be watching whether the debt paydown, once completed, gives Health Catalyst the financial flexibility to pursue partnerships or bolt-on acquisitions in its stated core, or whether the company enters a period of more cautious organic investment.
For Med-Metrix, the acquisition adds a recognised software brand in a segment where it already has deep operational expertise, and the combination could support cross-sell opportunities across its existing provider client base. How quickly it can accelerate Vitalware's growth beyond the $37 million revenue baseline will be a key indicator of deal rationale for both parties.